Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data now expected in Q1 2027.
Olema finished signing up patients for an important breast cancer study, but won't share results until 2027—making investors wait longer to see if the medicine works. When people have to wait longer for good news, they often sell their stock, so watch how the company uses this extra time to prepare.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.